HTS on Riboflavin and Terpene Biosynthetic Enzymes(RMI)

Information

  • Research Project
  • 7020393
  • ApplicationId
    7020393
  • Core Project Number
    R21NS053634
  • Full Project Number
    1R21NS053634-01
  • Serial Number
    53634
  • FOA Number
    RFA-RM-05-11
  • Sub Project Id
  • Project Start Date
    9/30/2005 - 18 years ago
  • Project End Date
    8/31/2006 - 17 years ago
  • Program Officer Name
    SCHEIDELER, MARK A
  • Budget Start Date
    9/30/2005 - 18 years ago
  • Budget End Date
    8/31/2006 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/23/2005 - 18 years ago

HTS on Riboflavin and Terpene Biosynthetic Enzymes(RMI)

DESCRIPTION (provided by applicant): Medical progress in the last century has dramatically reduced the morbidity and mortality caused by infectious diseases. On the other hand, infections by bacteria, fungi, protozoa and viruses continue to be the most important factor of mortality in developing countries. Even in developing countries, the rapidly progressing development of resistances against all presently used anti-infective agents generates this state of urgency for the development of novel chemotherapeutic agents for the control of infectious diseases. The enzymes of the recently discovered non-mevalonate pathway of terpene biosynthesis are known to be essential in gram negative bacteria and in Plasmodium spp., and the pathway has been established as a therapeutic target for malaria. Similarly, the proteins of the vitamin B2 biosynthetic pathway are known to be essential in gram negative bacteria and in yeasts. We are planning to use our expertise in the metabolic pathways mentioned above as the basis for the development of robust and rapid assay methods that are suitable for robotic processing. Specifically, assays will be developed for 4 enzymes of the non-mevalonate pathway and for 3 assays of the riboflavin pathway. All assays will be designed for photometric monitoring and will be suitable for the screening of large libraries comprising hundreds of thousands of chemical compounds. Based on our prior work, we can already say with certainty that the required reagents can be procured with an acceptable effort. These assays are planned to be used for the screening of a 100,000 compound library of drug like compounds at the High Throughput Screening Laboratory at the University of Kansas in cooperation with Profs. Cushman, George and Ye. Additional assay methods will be developed for rapid verification of hits obtained in these screens. Follow-up work in cooperation with Prof. Cushman will be directed at the development of candidate compounds into actual anti-infective drugs by medicinal chemistry methods.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R21
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    125000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    310
  • Ed Inst. Type
  • Funding ICs
    OD:125000\
  • Funding Mechanism
  • Study Section
    ZNS1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TECHNICAL UNIVERSITY OF MUNICH
  • Organization Department
  • Organization DUNS
    324179737
  • Organization City
    MUNICH
  • Organization State
  • Organization Country
    GERMANY
  • Organization Zip Code
  • Organization District
    GERMANY